Eagle Asset Management Inc. boosted its stake in shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 6.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,270,160 shares of the biotechnology company’s stock after buying an additional 135,374 shares during the period. Eagle Asset Management Inc. owned approximately 4.51% of Aimmune Therapeutics worth $46,674,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. SG Americas Securities LLC boosted its stake in shares of Aimmune Therapeutics by 10.1% in the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 499 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Aimmune Therapeutics during the second quarter valued at $333,000. Finally, American International Group Inc. boosted its stake in shares of Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares during the last quarter. 72.90% of the stock is owned by institutional investors and hedge funds.

Shares of Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at 21.39 on Friday. Aimmune Therapeutics, Inc. has a 52-week low of $14.01 and a 52-week high of $27.31. The stock’s market capitalization is $1.08 billion. The stock has a 50 day moving average of $20.63 and a 200 day moving average of $20.15.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.01. Analysts forecast that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current year.

WARNING: “Eagle Asset Management Inc. Has $46.67 Million Position in Aimmune Therapeutics, Inc. (AIMT)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/02/eagle-asset-management-inc-has-46-67-million-position-in-aimmune-therapeutics-inc-aimt.html.

Several brokerages have weighed in on AIMT. Zacks Investment Research cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, July 24th. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. ValuEngine raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Finally, Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Hold” and a consensus target price of $32.50.

In related news, insider Susan E. Barrowcliffe sold 15,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $20.26, for a total value of $303,900.00. Following the completion of the sale, the insider now directly owns 15,000 shares of the company’s stock, valued at $303,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen George Dilly sold 50,000 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total transaction of $1,073,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 188,470 shares of company stock valued at $3,942,092. 24.56% of the stock is owned by insiders.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.